Correction to: Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells (Medical Oncology, (2011), 28, 3, (878-887), 10.1007/s12032-010-9524-1);Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells

Medical Oncology

Volumn 28, Issue 3, 2011, Pages 878-887

  Guo, Zhenghui ^a   Huang, Hai ^a   Zeng, Lexiang ^a   Du, Tao ^b   Xu, Kewei ^a   Lin, Tianxin ^a   Jiang, Chun ^a   Dong, Wen ^a   Cao, Yi ^a   Chen, Jieqing ^a   Zhong, Weide ^c   Huang, Jian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Growth; Invasion; Migration; Prostate cancer; Prostate specific membrane antigen; RNA interference

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LENTIVIRINAE; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE;

EID: 80052432190     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-021-01527-5     Document Type: Erratum

References (30)

1. J Graham M Baker F Macbeth V Titshall 2008 Diagnosis and treatment of prostate cancer: summary of NICE guidance BMJ 336 610 612 18340076 10.1136/bmj.39498.525706.AD
2. J Cuzick G Fisher MW Kattan D Berney T Oliver CS Foster, et al. 2006 Long-term outcome among men with conservatively treated localised prostate cancer Br J Cancer 95 1186 1194 17077805 10.1038/sj.bjc.6603411 1:STN:280:DC%2BD28nktlSjtg%3D%3D
3. Y Kakehi 2003 Watchful waiting as a treatment option for localized prostate cancer in the PSA era Jpn J Clin Oncol 33 1 5 12604715 10.1093/jjco/hyg011
4. MA Rubin 2008 Targeted therapy of cancer: new roles for pathologists-prostate cancer Mod Pathol 21 Suppl. 2 S44 S55 18437173 10.1038/modpathol.2008.11 1:CAS:528:DC%2BD1cXltFeiu7Y%3D
5. WG Nelson AM De Marzo WB Isaacs 2003 Prostate cancer N Engl J Med 349 366 381 12878745 10.1056/NEJMra021562 1:CAS:528:DC%2BD3sXls1Sntrg%3D
6. JS Ross CE Sheehan HA Fisher RP Kaufman Jr P Kaur K Gray, et al. 2003 Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer Clin Cancer Res 9 6357 6362 14695135 1:CAS:528:DC%2BD3sXhtVSqurzN
7. GP Murphy TG Greene WT Tino AL Boynton EH Holmes 1998 Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen J Urol 160 2396 2401 9817391 10.1016/S0022-5347(01)62198-0 1:CAS:528:DyaK1cXnsFChtLk%3D
8. RS Israeli CT Powell JG Corr WR Fair WD Heston 1994 Expression of the prostate-specific membrane antigen Cancer Res 54 1807 1811 7511053 1:CAS:528:DyaK2cXisVWnurk%3D
9. SS Chang VE Reuter WD Heston PB Gaudin 2001 Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma Urology 57 1179 1183 11377343 10.1016/S0090- 4295(01)00983-9 1:STN:280:DC%2BD387hslOrtg%3D%3D
10. SD Sweat A Pacelli GP Murphy DG Bostwick 1998 Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 52 637 640 9763084 10.1016/S0090-4295(98)00278-7 1:STN:280:DyaK1cvjsVSnug%3D%3D
11. J Wang Y Cai R Penland S Chauhan RL Miesfeld M Ittmann 2006 Increased expression of the metastasis-associated gene Ehm2 in prostate cancer Prostate 66 1641 1652 16927306 10.1002/pros.20474 1:CAS:528:DC%2BD28Xht1Oktb%2FN
12. Y Li Z Tian SMA Rizvi NH Bander BJ Allen 2002 In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen Prostate Cancer Prostatic Dis 5 36 46 15195129 10.1038/sj.pcan.4500543 1:CAS:528: DC%2BD38Xjt1Ogu7s%3D
13. DB Kohn WF Anderson RM Blaese 1989 Gene therapy for genetic diseases Cancer Investig 7 179 192 10.3109/07357908909038283 1:STN:280: DyaK3c%2Fgt1aqtw%3D%3D
14. CR Dass PF Choong 2008 Gene therapy for osteosarcoma: steps towards clinical studies J Pharm Pharmacol 60 405 413 18380911 10.1211/jpp.60.4.0001 1:CAS:528:DC%2BD1cXkslSiur0%3D
15. MX Si YF Wei L Zhen XW Shuang L Xin FL Teng, et al. 2008 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin J Transl Med 6 55 64 10.1186/1479-5876-6-55
16. Grimm D, Kay MA. RNAi and gene therapy: a mutual attraction. Hematology Am Soc Hematol Educ Program. 2007;473-81.
17. Y Xueshi L Ting G Yuping Z Bohui M Wentong L Yamei 2009 Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1 Leuk Res 33 1114 1119 10.1016/j.leukres.2008.10.011
18. GJ Hannon 2002 RNA interference Nature 418 244 251 12110901 10.1038/418244a 1:CAS:528:DC%2BD38XltFGmu7Y%3D
19. K Lundstrom 2003 Latest development in viral vectors for gene therapy Trends Biotechnol 21 117 122 12628368 10.1016/S0167-7799(02)00042-2 1:CAS:528:DC%2BD3sXhs1Wrurk%3D
20. PL Sinn SL Sauter PB McCray Jr 2005 Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production Gene Ther 12 1089 1098 16003340 10.1038/sj.gt.3302570 1:CAS:528:DC%2BD2MXlvVGgurw%3D
21. B Dropulic 2005 Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells Curr Hematol Rep 4 300 304 16009045 1:CAS:528:DC%2BD28XktVanug%3D%3D
22. G Tiscornia O Singer IM Verma 2006 Design and cloning of lentiviral vectors expressing small interfering RNAs Nat Protoc 1 234 240 17406238 10.1038/nprot.2006.36 1:CAS:528:DC%2BD28XhtFOitbvO
23. L Liu Q Zhang Y Zhang S Wang Y Ding 2006 Lentivirus-mediated silencing of Tiam1 gene influences multiple functions of a human colorectal cancer cell line Neoplasia 8 917 924 17132223 10.1593/neo.06364 1:CAS:528:DC%2BD28Xht1eitrfJ
24. AK Gregorakis EH Holmes GP cMurphy 1998 Prostate-specific membrane antigen: current and future utility J Semin Urol Oncol 16 2 12 9508077 1:STN:280:DyaK1c7mslCqtA%3D%3D
25. AK Rajasekaran G Anilkumar JJ Christiansen 2005 Is prostate-specific membrane antigen a multifunctional protein? J Physiol Cell Physiol 288 975 981 10.1152/ajpcell.00506.2004
26. M Kawakami J Nakayama 1997 Enhanced expression of prostate-specific membrane antigen gene in situ hybridization Cancer Res 57 2321 2324 9192800 1:CAS:528:DyaK2sXjvFKitrY%3D
27. DS O'Keefe DJ Bacich WD Heston 2004 Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene Prostate 58 200 210 14716746 10.1002/pros.10319
28. Z Guo H Huang T Du 2008 Expression of prostate-specific membrane antigen (PSMA) after the transfection of shRNA lentivirus with PSMA construction in 293 cells Chin J Pathophysiol 24 1886 1890 1:CAS:528:DC%2BD1MXhtVyrsr7I Chinese
29. S Perner DH Matthias R Kim BS Rajal H Li P Mö ller, et al. 2007 Prostate-specific membrane antigen expression as a predictor of prostate cancer progression Human Pathol 38 696 701 10.1016/j.humpath.2006.11.012 1:CAS:528:DC%2BD2sXkt1ajtLY%3D
30. Z Weiming X Yong K Deling L Ranlu Z Zijian J Chengjun, et al. 2009 Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer Urol Oncol Semin Orig Investig 27 539 547 10.1016/j.urolonc.2008.05.003